Loading...
Loading...
CYCC| Name | Value |
|---|---|
| Revenues | 81.0 |
| Cost of Revenue | 64.0 |
| Gross Profit | 17.0 |
| Operating Expense | 1,009.0 |
| Operating I/L | -992.0 |
| Other Income/Expense | 4.0 |
| Interest Income | 0.0 |
| Pretax | -988.0 |
| Income Tax Expense | 0.0 |
| Net Income/Loss | -988.0 |
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development of medicines for cancer and proliferative diseases. Their product pipeline includes fadraciclib, a cyclin dependent kinase inhibitor in Phase 1/2 clinical trials for solid tumors and chronic lymphocytic leukemia, and CYC140, a polo-like kinase inhibitor in Phase 1/2 trials for advanced leukemias and solid tumors. Additionally, they are developing Sapacitabine, an orally available prodrug of CNDAC for acute myeloid leukemia and myelodysplastic syndrome, and seliciclib, a CDK inhibitor in Phase 2 trials for Cushing's disease and advanced rheumatoid arthritis.
